ESMO Preceptorship on Prostate Cancer

PROGRAMME

ESMO PRECEPTORSHIP

LUGANO SWITZERLAND
16-17 DECEMBER 2025

CO-CHAIRS

Karim Fizazi, France

Silke Gillessen, Switzerland

esmo.org

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

ESMO PRECEPTORSHIP PROGRAMME
PROSTATE CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Lugano, Switzerland
16-17 December 2025

CO-CHAIRS
Karim Fizazi, France
Silke Gillessen, Switzerland

SPEAKERS
Elena Castro, Spain
Glen Kristiansen, Germany
Daniela Oprea-Lager, Netherlands
Yüksel Ürün, Türkiye
Jochen Walz, France
Thomas Zilli, Switzerland

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points.**
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by

AstraZeneca

Supported by a grant from Pfizer Inc.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

Tuesday, 16 December 2025

09:00-09:10 10’	Opening and welcome	
10’	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR Silke Gillessen, CH

09:10-10:50 100’	SESSION 1 Screening, diagnosis, staging and localised prostate cancer	Chairs: Glen Kristiansen, DE Jochen Walz, FR
15’	PSA screening and diagnosis	Jochen Walz, FR
10’	Staging	Jochen Walz, FR
15’	Pathological diagnosis for the clinician (including variants of PCa)	Glen Kristiansen, DE
15’	Treatment of localised prostate cancer according to risk category	Jochen Walz, FR
15’	Radiotherapeutic approaches for localised prostate cancer	Thomas Zilli, CH
15’	Q&A	All
15’	Participants clinical case discussion (1x15’)	Faculty

10:50-11:20	Coffee break	

11:20-12:45 85’	SESSION 2 Biochemical relapse	Chairs: Yüksel Ürün, TR Thomas Zilli, CH
15’	Biochemical relapse: Definition and diagnostic algorithm	Yüksel Ürün, TR
20’	Rising PSA after radical local treatment: Prognosis, indications for salvage local treatments, salvage vs adjuvant treatments	Thomas Zilli, CH
20’	Use of early vs deferred systemic treatments in high-risk localised CaP and biochemical failures	Thomas Zilli, CH
15’	Q&A	All
15’	Participants clinical case discussion (1x15’)	Faculty

12:45-13:45	Lunch	

13:45-15:25 100’	SESSION 3 Systemic treatment options and molecular characterisation	Chairs: Elena Castro, ES Jochen Walz, FR
20’	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gillessen, CH
20’	Chemotherapy (taxanes and platins), PARP-inhibitors and Radium-223, mechanism of action, main efficacy results in castration-resistant prostate cancer (CRPC) and toxicities	Elena Castro, ES
15’	Bone health agents, mechanism of action, efficacy and toxicities	Yüksel Ürün, TR
15’	Molecular characterisation: Germline and somatic testing	Elena Castro, ES
15’	Q&A	All

15'	Participants clinical case discussion (1x15')	Faculty
15:25-15:55	Coffee break	
15:55-17:20 85'	**SESSION 4 Castration-sensitive metastatic prostate cancer**	**Chairs: Elena Castro, ES Silke Gillessen, CH**
20'	Metastatic castration-sensitive prostate cancer (mCSPC): Doublets	Silke Gillessen, CH
20'	Non metastatic CRPC: Current treatment	Yüksel Ürün, TR
15'	Oligo-metastatic disease: What treatment?	Thomas Zilli, CH
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
19:30	Networking Dinner	

Wednesday, 17 December 2025

09:00-10:45 105'	**SESSION 5 Non metastatic and metastatic castration-resistant disease**	**Chairs: Elena Castro, ES Yüksel Ürün, TR**
20'	Triplet and quadruplet options (mCSPC)	Karim Fizazi, FR
20'	Metastatic CRPC: Current treatment	Silke Gillessen, CH
20'	PSMA-based therapies	Daniela Oprea-Lager, NL
15'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
10:45-11:15	Coffee break	
11:15-12:20 65'	**SESSION 6 Metastatic castration-resistant disease**	**Chairs: Karim Fizazi, FR Silke Gillessen, CH**
15'	Treatment in frail patients with mCRPC	Elena Castro, ES
20'	Experimental treatments for mCRPC	Karim Fizazi, FR
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
12:20-12:30 10'	**Conclusion and farewell**	**Karim Fizazi, FR Silke Gillessen, CH**
12:30-13:30	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion